secwatch.observer — SEC 8-K summary ====================================== Issuer: Summit Therapeutics Inc. (SMMT) CIK: 0001599298 Form: 8-K Filed at: 2026-11-16T11:08:15+00:00 Accession: 0001599298-26-000092 Event type: regulatory Sentiment: negative Materiality: 0.92 Item codes: 8.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 FDA issues Complete Response Letter for Summit's ivonescimab BLA in EGFR-mutant NSCLC -------------------------------------------------------------------------------- - FDA said substantial evidence of effectiveness is not established without a statistically significant overall survival benefit; PFS benefit alone failed to support a positive benefit-risk profile. - HARMONi met its PFS primary endpoint, but the primary OS analysis showed only a positive trend that was not statistically significant. - Post-hoc longer follow-up showed OS hazard ratio of 0.76 across the full, Asian and western patient populations. - Safety: 16 patients (7.3%) discontinued ivonescimab for TRAEs vs 11 (5.0%) on placebo; treatment-related deaths 4 (1.8%) vs 5 (2.3%). - Ivonescimab remains unapproved in the U.S. and Europe (China approval May 2024); Summit cites five positive Phase III studies and ongoing HARMONi-3, -7, -GI3, -GU1 trials. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/0001599298-26-000092-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm HTML page: https://secwatch.observer/filing/0001599298-26-000092 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer